Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


TAVR Researchers Look To Lower-Risk Patients, Less Data Demands

This article was originally published in The Gray Sheet

Executive Summary

Edwards Lifesciences' Sapien 3 valve looked good at the annual American College of Cardiology conference, including in intermediate-risk patients. Could it mean less follow-up demands for future approvals? Meanwhile, Medtronic continued to press its status as the only company with a TAVR device shown superior to surgery.

You may also be interested in...

US FDA Approves First Intermediate-Risk Indication For TAVR

The expanded indication for Edwards' Sapien XT and Sapien 3 arrives about when the company had predicted.

Medtronic Nabs First Superiority Outcome In TAVR Versus Surgery

Data from Medtronic’s CoreValve High Risk Study provide the firm with significant momentum toward expanding the FDA label for its transcatheter aortic valve replacement device. Based on the results, FDA says no advisory panel will need to meet for the firm’s high-risk surgery submission. Observers say the jury is still out on CoreValve versus Sapien question.

US FDA Lab Test Rule Cites Explosion In Companion Diagnostics, COVID Lessons

FDA launches what it hopes will the final push to reform the regulatory oversight system for lab-developed tests by proposing a relatively rapid transition period to require essentially all LDTs to comply with the existing regulations for in vitro diagnostics. Legislation, litigation, and industry negotiation will likely shape the final product.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts